Covista Gestione
Criteri Gestione verificati 2/4
Covista Il CEO è Steve Beard, nominato in Sep2021, e ha un mandato di 4.67 anni. la retribuzione annua totale è $ 17.24M, composta da 5.8% di stipendio e 94.2% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 1.08% delle azioni della società, per un valore di $ 45.81M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 4.1 anni e 7.6 anni.
Informazioni chiave
Steve Beard
Amministratore delegato
US$17.2m
Compenso totale
| Percentuale dello stipendio del CEO | 5.80% |
| Mandato del CEO | 4.7yrs |
| Proprietà del CEO | 1.1% |
| Durata media del management | 4.1yrs |
| Durata media del Consiglio di amministrazione | 7.6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Nuova narrazione • Apr 22
Health Care Workforce Shortages Will Pressure Capacity Expansion Yet Support Long Term Potential
Catalysts About Covista Covista is a health care education provider focused on training nurses, physicians, veterinarians and behavioral health professionals at scale. What are the underlying business or industry changes driving this perspective?
Nuova narrazione • Apr 08
Health Care Workforce Shortages And Digital Learning Will Support This Bullish Long Term Thesis
Catalysts About Covista Covista provides higher education programs focused on health care and related professional fields. What are the underlying business or industry changes driving this perspective?
Nuova narrazione • Mar 24
Health Care Workforce Shortages And Flexible Learning Will Support Stronger Long Term Outcomes
Catalysts About Covista Covista focuses on large scale health care education programs serving nursing, medical, veterinary and allied health students across the United States. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Mar 13
Covista: A Mispriced Bet On The Healthcare Worker Shortage
Summary Covista is trading significantly below its intrinsic value despite short-term headwinds at Chamberlain University. All segments are growing revenue; Walden University’s 27% revenue and 13% enrollment growth offset Chamberlain’s 1% enrollment decline. Key risks include heavy reliance on Title IV funding and regulatory changes, though long-term healthcare demand and AI-driven career shifts support growth and limit risk. Read the full article on Seeking AlphaArticolo di analisi • Sep 27
With EPS Growth And More, Adtalem Global Education (NYSE:ATGE) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Articolo di analisi • Aug 07
Adtalem Global Education (NYSE:ATGE) Has A Pretty Healthy Balance Sheet
NYSE:ATGE 1 Year Share Price vs Fair Value Explore Adtalem Global Education's Fair Values from the Community and select...Articolo di analisi • Jul 07
An Intrinsic Calculation For Adtalem Global Education Inc. (NYSE:ATGE) Suggests It's 44% Undervalued
Key Insights Adtalem Global Education's estimated fair value is US$221 based on 2 Stage Free Cash Flow to Equity...Articolo di analisi • May 13
There's Reason For Concern Over Adtalem Global Education Inc.'s (NYSE:ATGE) Massive 27% Price Jump
Adtalem Global Education Inc. ( NYSE:ATGE ) shareholders have had their patience rewarded with a 27% share price jump...Articolo di analisi • May 07
If EPS Growth Is Important To You, Adtalem Global Education (NYSE:ATGE) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Articolo di analisi • Apr 24
Is Adtalem Global Education (NYSE:ATGE) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Mar 25
Adtalem Global Education Inc. (NYSE:ATGE) Shares Could Be 48% Below Their Intrinsic Value Estimate
Key Insights Adtalem Global Education's estimated fair value is US$198 based on 2 Stage Free Cash Flow to Equity...Articolo di analisi • Mar 11
Subdued Growth No Barrier To Adtalem Global Education Inc.'s (NYSE:ATGE) Price
With a median price-to-earnings (or "P/E") ratio of close to 17x in the United States, you could be forgiven for...Articolo di analisi • Feb 24
Is There Now An Opportunity In Adtalem Global Education Inc. (NYSE:ATGE)?
Adtalem Global Education Inc. ( NYSE:ATGE ), is not the largest company out there, but it saw a decent share price...Seeking Alpha • Feb 21
Adtalem Global Education: Surging On Registered Nurse Shortage
Summary Adtalem Global Education Inc.'s financial performance has surged with an underlying nationwide shortage of Registered Nurses and in mental health professionals. A shortage is expected to persist — Adtalem still looks to benefit from secular trends in an aging population, while the long-term performance depends on universities' ability to expand capacity. ATGE stock's surge already reflects a good mid-term earnings performance, making long-term growth required for significant returns. I estimate a fair value of $109.5. Read the full article on Seeking AlphaArticolo di analisi • Jan 21
With EPS Growth And More, Adtalem Global Education (NYSE:ATGE) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Articolo di analisi • Dec 19
These 4 Measures Indicate That Adtalem Global Education (NYSE:ATGE) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Dec 17
Adtalem Global Education Still Offers Competitive PEG Ratio And Substantial Share Buybacks
Summary The company has shown significant financial progress with improving EBIT and profit margins, indicating efficient cost management. Current valuation metrics suggest the company is rather cheaply priced, despite the good run in 2024. The future outlook remains positive, but investors should be aware of potential risks, such as the debt or future competitive threats from robotics. Read the full article on Seeking AlphaArticolo di analisi • Nov 26
Adtalem Global Education Inc.'s (NYSE:ATGE) Shares Climb 27% But Its Business Is Yet to Catch Up
Adtalem Global Education Inc. ( NYSE:ATGE ) shareholders would be excited to see that the share price has had a great...Articolo di analisi • Oct 31
Should You Think About Buying Adtalem Global Education Inc. (NYSE:ATGE) Now?
Adtalem Global Education Inc. ( NYSE:ATGE ), is not the largest company out there, but it led the NYSE gainers with a...Articolo di analisi • Oct 16
Should You Be Adding Adtalem Global Education (NYSE:ATGE) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Oct 04
Adtalem Global Education Faces Problems But Is Growing Steadily
Summary Adtalem Global Education focuses on medical and veterinary education, showing solid profitability and potential growth in a booming healthcare industry. Despite a current ratio below 1.0, ATGE maintains a reasonable price/book ratio and generates significant operating cash flow, indicating financial stability. Risks include reliance on government financial aid, maintaining accreditation, and ensuring student placements in healthcare jobs, which are crucial for sustaining reputation and revenue. With projected revenue growth and a forward P/E ratio of 13.12, Adtalem Global is a cautious buy, offering portfolio diversity in a growing sector. Read the full article on Seeking AlphaArticolo di analisi • Sep 16
Adtalem Global Education (NYSE:ATGE) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Articolo di analisi • Aug 29
Adtalem Global Education Inc.'s (NYSE:ATGE) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 20.7x Adtalem Global Education Inc. ( NYSE:ATGE ) may be sending bearish...Articolo di analisi • Aug 14
We Think Adtalem Global Education's (NYSE:ATGE) Robust Earnings Are Conservative
Even though Adtalem Global Education Inc.'s ( NYSE:ATGE ) recent earnings release was robust, the market didn't seem to...Articolo di analisi • Jul 28
Should You Think About Buying Adtalem Global Education Inc. (NYSE:ATGE) Now?
While Adtalem Global Education Inc. ( NYSE:ATGE ) might not have the largest market cap around , it led the NYSE...Seeking Alpha • Jul 27
Adtalem Global Education: Still Undervalued After The Latest Rally
Summary Adtalem Global Education is set to report earnings on August 6th. The company specializes in healthcare education, with Chamberlain and Walden Universities under its wing, showing revenue growth post Walden acquisition. Financials show decent margins, but efficiency metrics trending down, with potential for top-line growth and margin expansion in the future. Read the full article on Seeking AlphaArticolo di analisi • Jul 12
Does Adtalem Global Education (NYSE:ATGE) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Articolo di analisi • Jun 14
Adtalem Global Education (NYSE:ATGE) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Seeking Alpha • May 19
Adtalem Global Education: A Leading Healthcare Educator In A Growing Industry
Summary ATGE has demonstrated robust revenue growth and strong profit margins over the past three years. ATGE's 3Q24 earnings showed year-over-year revenue growth of 11.8%, driven by growth in enrollment and tuition rates. The healthcare industry is facing significant labour shortages, which are expected to impact hospitals growth targets and outlook. ATGE plays a crucial role in training and providing healthcare professionals. Read the full article on Seeking AlphaAnalisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$250m |
| Dec 31 2025 | n/a | n/a | US$254m |
| Sep 30 2025 | n/a | n/a | US$247m |
| Jun 30 2025 | US$17m | US$1m | US$233m |
| Mar 31 2025 | n/a | n/a | US$229m |
| Dec 31 2024 | n/a | n/a | US$204m |
| Sep 30 2024 | n/a | n/a | US$172m |
| Jun 30 2024 | US$14m | US$987k | US$138m |
| Mar 31 2024 | n/a | n/a | US$111m |
| Dec 31 2023 | n/a | n/a | US$122m |
| Sep 30 2023 | n/a | n/a | US$108m |
| Jun 30 2023 | US$8m | US$950k | US$102m |
| Mar 31 2023 | n/a | n/a | US$79m |
| Dec 31 2022 | n/a | n/a | US$35m |
| Sep 30 2022 | n/a | n/a | US$47m |
| Jun 30 2022 | US$9m | US$828k | -US$36m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | n/a | n/a | -US$15m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | US$3m | US$600k | US$63m |
| Mar 31 2021 | n/a | n/a | US$139m |
| Dec 31 2020 | n/a | n/a | US$269m |
| Sep 30 2020 | n/a | n/a | US$246m |
| Jun 30 2020 | US$2m | US$598k | US$220m |
| Mar 31 2020 | n/a | n/a | US$208m |
| Dec 31 2019 | n/a | n/a | US$89m |
| Sep 30 2019 | n/a | n/a | US$130m |
| Jun 30 2019 | US$2m | US$536k | US$107m |
Compensazione vs Mercato: La retribuzione totale di Steve ($USD 17.24M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 7.00M ).
Compensazione vs guadagni: La retribuzione di Steve è aumentata di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Steve Beard (54 yo)
4.7yrs
Mandato
US$17,244,988
Compensazione
Mr. Stephen W. Beard, also known as Steve, J.D., serves as an Independent Director at Planet Fitness, Inc. since February 9, 2026. He served as Chief Operating Officer at Adtalem Global Education Inc. sinc...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Chairman | 4.7yrs | US$17.24m | 1.08% $ 45.8m | |
| Senior VP & CFO | 5.1yrs | US$2.02m | 0.13% $ 5.7m | |
| Senior VP of Institutional Support Services | 4.9yrs | US$1.65m | 0.096% $ 4.1m | |
| Chief Growth & Innovation Officer and President of Walden University | 4yrs | US$2.59m | 0.069% $ 2.9m | |
| President of Adtalem Medical & Veterinary | 2.1yrs | US$1.62m | 0.022% $ 925.9k | |
| VP & Chief Accounting Officer | 4.1yrs | Nessun dato | 0.0063% $ 268.7k | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Senior VP & Chief Human Resources Officer | 1.7yrs | Nessun dato | 0.0083% $ 351.8k | |
| Senior VP & Chief Corporate Affairs Officer | 1yr | Nessun dato | Nessun dato | |
| President of Chamberlain University | no data | Nessun dato | Nessun dato | |
| President of Chamberlain University | 7.8yrs | US$1.14m | 0.083% $ 3.5m | |
| Vice President of Treasury & Risk Management | no data | Nessun dato | Nessun dato |
4.1yrs
Durata media
55yo
Età media
Gestione esperta: Il team dirigenziale di CVSA è considerato esperto (durata media dell'incarico 4.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO & Chairman | 4.7yrs | US$17.24m | 1.08% $ 45.8m | |
| Director Emeritus | no data | US$108.37k | Nessun dato | |
| Director Emeritus | 12.5yrs | US$95.00k | Nessun dato | |
| Independent Director | 9.3yrs | US$250.17k | 0.026% $ 1.1m | |
| Lead Independent Director | 9.9yrs | US$251.42k | 0.41% $ 17.3m | |
| Independent Director | 6.1yrs | US$225.17k | 0.054% $ 2.3m | |
| Independent Director | 7.6yrs | US$237.67k | 0.020% $ 847.5k | |
| Director | 17.5yrs | US$273.17k | 0.13% $ 5.4m | |
| Independent Director | 6.1yrs | US$237.67k | 0.040% $ 1.7m | |
| Independent Director | 2.3yrs | US$225.17k | 0.0034% $ 142.7k | |
| Independent Director | 8yrs | US$237.67k | 0.047% $ 2.0m | |
| Independent Director | 3.9yrs | US$225.17k | 0.044% $ 1.9m |
7.6yrs
Durata media
66yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CVSA sono considerati esperti (durata media dell'incarico 7.6 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/26 19:36 |
| Prezzo dell'azione a fine giornata | 2026/05/26 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/06/30 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Covista Inc. è coperta da 23 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Gary Bisbee | Barclays |
| Alexander Paris | Barrington Research Associates, Inc. |
| Jeffrey Silber | BMO Capital Markets Equity Research |